Following a full submission
AWMSG advice |
|||
| Status: Recommended with restrictions | |||
Dequalinium chloride (Fluomizin®) for the treatment of bacterial vaginosis is recommended as an option for restricted use within NHS Wales. Dequalinium chloride (Fluomizin®) for the treatment of bacterial vaginosis is restricted for use after initial treatment is ineffective or not tolerated as an alternative option to clindamycin vaginal cream. Dequalinium chloride (Fluomizin®) is not recommended for use within NHS Wales outside of this population. |
|||
|
|||
Medicine details |
|||
| Medicine name | dequalinium chloride (Fluomizin®) | ||
| Formulation | 10 mg vaginal tablet | ||
| Reference number | 2775 | ||
| Indication | Treatment of bacterial vaginosis after initial treatment is ineffective or not tolerated as an alternative option to clindamycin vaginal cream |
||
| Company | Kora Corporation Ltd trading as Kora Healthcare | ||
| BNF chapter | Obstetrics, gynaecology & urinary tract disorders | ||
| Submission type | Full | ||
| Status | Recommended with restrictions | ||
| Advice number | 3416 | ||
| NMG meeting date | 05/10/2016 | ||
| AWMSG meeting date | 09/11/2016 | ||
| Ratification by Welsh Government | 18/11/2016 | ||
| Date of issue | 21/11/2016 | ||
| Date of last review | August 2020 | ||